Leukolectin Polypeptide for Autoimmune Disorder Treatment

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for autoimmune and inflammatory disorders, as well as skin damage, often come with significant side effects and are not always effective in managing chronic conditions such as rheumatoid arthritis and gastrointestinal inflammation.

Innovation Solution

The development of a polypeptide called leukolectin, which is specifically expressed in human leukocytes, and its encoding nucleic acid sequence, which can be used to treat autoimmune and inflammatory disorders by promoting normal healing processes and immune responses.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current treatments for autoimmune and inflammatory disorders are used, then immune response modulation is achieved, but significant side effects occur

Engineering Contradiction:

Improveeffectiveness of treatmentVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses leukolectin as an intermediary molecule that naturally mediates immune recognition and regulation. Instead of directly suppressing immune responses with exogenous drugs, the invention introduces a natural lectin protein that acts as a mediator between immune cells, restoring balanced immune function without the harsh side effects of conventional immunosuppressants

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The invention leverages the body's own inherent healing processes by introducing leukolectin, which triggers and enhances the body's natural immune regulation mechanisms. The treatment works by activating self-service repair and regulation systems rather than imposing external chemical suppression, thereby avoiding significant side effects

Inventive Principle:

Principle #25Self-service

2Object-affected harmful factors

If current treatments for chronic autoimmune conditions are administered, then symptom management is achieved, but treatment effectiveness is insufficient

Engineering Contradiction:

Improveinflammation reductionVSAvoidtreatment effectiveness

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent converts the harmful autoimmune response into a beneficial therapeutic effect by using leukolectin to redirect misdirected immune responses. The lectin binds to specific carbohydrate structures on immune cells, converting pathogenic autoimmunity into regulated immune function that reduces inflammation while maintaining immune surveillance

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Leukolectin has been shown to effectively treat autoimmune and inflammatory disorders, particularly of the skin, by binding to specific receptors and triggering inherent healing processes, reducing inflammation and improving skin conditions with minimal side effects.

Implementation Method 1

a polypeptide, namely a lectin... binding to specific receptors and triggering inherent healing processes

Methodology Applied

Scientific EffectLectin-carbohydrate binding: Absorption (physical)

Data Source

PatentUS10124034B2Leukolectins and uses thereof

Publication Date: 2018.11.13 LEUKOLECT

AI summary

The present invention relates to a polypeptide, described as a lectin, its encoding nucleic acid sequence and antibodies to the polypeptide and their use in various medical applications, particularly for treating or preventing an autoimmune disorder, an inflammatory disorder or damaged skin in an animal.